A Phase 2 Study to Evaluate the Safety and Efficacy of Switching Oral Antiviral Treatment (OAV) in Viralogically Suppressed Chronic Hepatitis B Patients with Renal and/or Hepatic Impairment

August 07, 2018
https://clinicaltrials.gov/ct2/show/NCT03180619
Gastroenterology Hepatology
Principal Investigator: Syed-Mohammed R Jafri, MD
Hep B, hep, b, hepatitis b, TAF, TDF, oral antiviral treatment, oav, renal impairment, hepatic impairment, hep b and liver disease, hep b and kidney disease, switching hep b antiviral
Open